Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Generics
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Generics
Viatris has announced that the antitrust division of the US Department of Justice (DOJ) has concluded its investigation into Mylan and its former president, Rajiv Malik. 3 July 2024
Generics
An activist investor has renewed its effort to prevent Taro Pharmaceutical from accepting a buyout bid from Sun Pharmaceutical. 24 April 2024
Generics
Generic drugmaker Apotex has reached an agreement to acquire fellow Canada-based Searchlight Pharma. 5 April 2024
Generics
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
Generics
Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. 11 March 2024
Generics
In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical is to hive off its active pharmaceutical ingredient (API) business. 1 February 2024
Generics
Sun Pharmaceutical Industries of India announced its intention to acquire all outstanding shares of US generics drugmaker Taro Pharmaceutical Industries at a price of $43 per share in cash, the companies announced. 19 January 2024
Generics
Taiwan’s Bora Pharmaceuticals is to acquire Upsher-Smith Laboratories, a US generics manufacturer. 17 January 2024
Generics
South Africa's largest drugmaker Aspen Pharmacare has announced an agreement with newly-independent generics drugmaker Sandoz, related to its Chinese business. 7 December 2023
Generics
Portuguese contract development and manufacturing organization (CDMO) Hovione has acquired the start-up ExtremoChem for an undisclosed amount. 20 November 2023
Generics
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year. 8 November 2023
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Generics
Indian drugmaker Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), which focuses on producing active pharmaceutical ingredients (APIs). 22 September 2023
Generics
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
Generics
Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy. 14 April 2023
Generics
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Generics
Private equity firm SK Capital Partners has entered into a deal to acquire Apotex Pharmaceutical Holdings, a Canada-based generic drugmaker with products across all major therapeutic areas for patients around the world. 29 September 2022
Generics
Global drugs behemoth Pfizer (NYSE: PFE) and Zhejiang Hisun Pharmaceutical (SSE Code: 600267), a leading Chinese manufacturers of active pharmaceutical ingredients (APIs) have signed a framework agreement, advancing their previously announced memorandum of understanding (MOU) to establish a joint venture to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets (The Pharma Letter June 3, 2011). 19 February 2012
Generics
Merck & Co (NYSE: MRK) says it has formed a new joint venture with Supera Farma Laboratorios, a Brazilian drugmaker co-owned by Cristalia and Eurofarma, to market, distribute and sell a portfolio of innovative pharmaceutical and branded generic products from Merck, Cristalia and Eurofarma solely in the Brazilian retail sector. 16 February 2012
Generics
In a regulatory filing with the Hong Kong Stock Exchange yesterday, Shanghai Pharmaceuticals Holding (SHSE: 601607) says it has resolved to gain control of Changzhou Kony Pharma in order to enhance its strength in the manufacturing of special active pharmaceutical ingredients (APIs) and enrich its product portfolio, as well as to establish a manufacturing, research and development center for special APIs. 7 February 2012
Generics
Icelandic generics drugmaker Actavis and Poland's Bioton (WSE: BIO) have formed a joint venture company for the development and registration of insulins, including analogue insulins, aiming to shake up the diabetes market. 31 January 2012
Generics
German drugmakers STADA Arzneimittel (SAZ: GR) and family-owned Grunenthal have agreed on the purchase of a branded product portfolio including the associated sales structures, also for the EU markets in Central Europe (including Poland). 30 January 2012
Generics
US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has kicked off the new year with the acquisition of Ascent Pharmahealth, the Australia and Southeast Asia generic pharmaceutical business of India-based Strides Arcolab (BO: 532581), for A$375 million ($395.6 million) in cash. 24 January 2012
Generics
Fast-growing Jordan headquartered Hikma Pharmaceuticals (LSE: HIK) says that it has increased its stake in Morocco-based Promopharm (Societe de Promotion Pharmaceutique du Maghreb) to 94.1%, adding to the 63.6% stake acquired last year (The Pharma Letter October 15, 2011). 22 January 2012
Generics
Indian drugmaker Dishman Pharmaceuticals and Chemicals says that its Swiss unit has acquired a contract research and manufacturing firm from France-based Creapharm Group, Creapharm Parenterals, according to media reports, including Reuters and The Economic Times of India. Financial terms of the transaction were not disclosed, but the news saw the Indian firm's shares rise 3% to 49 rupees. 17 January 2012
Generics
Danish CNS drug specialist Lundbeck (LUND: DC) says it has entered into an agreement with USA-based niche generic drugmaker Akorn (Nasdaq: AKRX) to sell a portfolio of three off-patent, branded, hospital-based injectables products comprising Nembutal (pentobarbital sodium injection, USP), Cogentin (benztropine mesylate injection) and Intravenous Sodium Diuril (chlorothiazide sodium). 23 December 2011
Generics
Miami, USA-based OPKO Health (NYSE: OPK), which is controlled by Israeli generics giant Teva Pharmaceutical Industries (Nasdaq: TEVA), has entered into an agreement to acquire FineTech Pharmaceutical, a profitable Israeli company which develops and produces high value, high potency active pharmaceutical ingredients (APIs), for a consideration of $27.5 million. The transaction is expected to close on December 29, 2011. 22 December 2011
Generics
Indian drug firm Zydus Cadila says it has acquired a 100% stake in Biochem, described as one of the top 40 pharma companies in India, for an undisclosed amount. A privately-held company headquartered in Mumbai, Biochem is a well-integrated pharma player with a presence in the antibiotics, cardiovascular, anti-diabetic and oncology segments. Biochem has reported sales of 2.65 billion rupees ($42.2 million) for the year 2010-2011. 21 December 2011
Generics
Swiss branded and generic drugmaker Acino Pharma (SIX: ACIN) and Israel's Teva Pharmaceutical Industries (Nasdaq: TEVA) have entered into an agreement for Acino to additionally acquire the Latin American (LATAM) and Asian businesses of Mepha and the Mepha site in Aesch, including production and R&D facilities, for a total consideration of 94 million euros ($122.6 million) Teva will market and develop the Mepha brand in Switzerland. 19 December 2011
Generics
US medical products and generic drugmaker Covidien (NYSE: COV) says that it plans to spin off its pharmaceuticals business - which generates around $2 billion in annual sales - into a stand-alone public company. The decision comes after several years of evaluating options which, according to observers, included talks to sell the drugs business for $3-$4 billion that failed to materialize. The news saw Covidien's shares rise 3.3% to $43.55 by close yesterday. 16 December 2011
Generics
It was a busy couple of days for Anglo-Swedish drug major AstraZeneca (LSE: AZN), with the company yesterday announcing a new set of cutbacks in the number of US employees, with a near quarter reduction in its sales staff, and this morning revealing it is to buy a generic drugmaker in China, so expanding its presence in emerging markets and adding to the already $500 million it has invested in China since setting up there in 1993. 8 December 2011
Generics
The generic drugs sector's role as the provider of affordable drugs has widely benefitted public and private health payers keen to control costs. But in the current economic climate, downward pressure on prices is impacting the generic sector, with increases in acquisition and strategic partnering now firmly part of the competitive landscape. 7 December 2011
Generics
Iceland-headquartered generic drugmaker Actavis says it has acquired 100% of the shares in PharmaPack International BV for an undisclosed amount. PharmaPack is based in Zoetermeer, the Netherlands, and is a specialist in packaging pharmaceutical as well as biotechnological products. 4 December 2011
Generics
California, USA-based generic drugmaker SOHM (Pinksheets: SHMN) has announced the acquisition of business and brands of privately owned Novatrend Medicament, a manufactures pharmaceutical raw material based in Pune, India. Financial terms of the deal were not disclosed. 28 November 2011
Generics
Indian drugmaker Lupin (LOPN: BO) has entered into an agreement with Japanese health care provider I'rom Holdings (IH) to acquire up to 100% of the outstanding shares of its subsidiary I'rom Pharmaceutical. The transaction, financial terms of which are not being disclosed, is being handled via Lupin's Japanese subsidiary Kyowa Pharmaceuticals, which it acquired in 2007, and is aimed at providing entry into Japan's injectable generics market. 18 November 2011
Generics
German drugmaker STADA Arzneimittel (SAZ: GR) has reached agreement with Switzerland's Spirig Pharma to purchase Spirig's generics business including the respective sales structures by STADA for a total of around 97 million Swiss francs ($109.2 million). 11 November 2011
Generics
Chinese drugmaker Biostar Pharmaceuticals (Nasdaq: BSPM) says that it has completed the previously-announced acquisition of Shaanxi Weinan Huaren Pharmaceuticals for an aggregate cash price of 61 million renminbi (around $9.6 million; The Pharma Letter October 11). Additionally, it has changed the name of the acquired company changed to Shaanxi Weinan Aoxing Pharmaceuticals. 25 October 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze